SERPINB2, an Early Responsive Gene to Epigallocatechin Gallate, Inhibits Migration and Promotes Apoptosis in Esophageal Cancer Cells

Cells. 2022 Nov 30;11(23):3852. doi: 10.3390/cells11233852.

Abstract

Esophageal cancer is a lethal disease that frequently occurs in developing countries, the incidence of which could be declined by drinking EGCG-enriched drinks or food. SERPINB2, whose complex functions and regulations are not yet fully understood, are induced by multiple inflammatory molecules and anti-tumor agents. Here, we identify 2444 EGCG-regulated genes in esophageal cancer cells, including SERPINB2. EGCG treatment recruits NF-κB at the promoter and enhancers of SERPINB2 and activates gene transcription, which is repressed by NF-κB knockdown or inhibition. Loss of SERPINB2 leads to a faster migration rate and less expression of Caspase-3 in cancer cells. Our study demonstrates that SERPINB2 is a new tumor-suppressor gene involved in cell movement and apoptosis and could be a therapeutic target for esophageal cancer.

Keywords: EGCG; SERPINB2; apoptosis; esophageal cancer.

MeSH terms

  • Apoptosis* / genetics
  • Cell Line, Tumor
  • Cell Movement / genetics
  • Esophageal Neoplasms* / drug therapy
  • Esophageal Neoplasms* / genetics
  • Esophageal Neoplasms* / pathology
  • Genes, Tumor Suppressor
  • Humans
  • Intracellular Signaling Peptides and Proteins* / genetics
  • NF-kappa B / metabolism

Substances

  • NF-kappa B
  • SERPINB2 protein, human
  • Intracellular Signaling Peptides and Proteins
  • epigallocatechin gallate